{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-009286","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.233532+00:00","generated_at":"2026-05-22T05:35:28.907990+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cingulate Q1 net loss $3.8M, cash $9.5M; NDA submission for CTx-1301 on track mid-2025","bullets":["Net loss of $3.8M ($1.04 per share) for Q1 2025, compared to $3.0M in Q1 2024.","Cash and equivalents $9.5M at March 31, 2025; cash runway into Q4 2025 beyond NDA submission.","Pre-NDA meeting with FDA completed April 2, 2025; NDA submission for CTx-1301 targeted mid-2025.","Received $3M non-dilutive grant from private foundation to accelerate CTx-2103 (buspirone) anxiety asset.","Working capital $4.9M at Q1 end, down from $7.7M at Dec 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-009286","json":"https://secwatch.observer/filing/0001641172-25-009286.json","markdown":"https://secwatch.observer/filing/0001641172-25-009286.md","text":"https://secwatch.observer/filing/0001641172-25-009286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000164117225009286/0001641172-25-009286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000164117225009286/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:35:28.907990+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}